Tetsuya Suhara

Q: What Schools Are Affiliated With Tetsuya Suhara

Tetsuya Suhara is affiliated with the following schools: Tohoku University, Tokyo Medical University, University of Cambridge

Tetsuya Suhara's AcademicInfluence.com Rankings

Tetsuya Suhara

Computer Science

#8637

World Rank

#9081

Historical Rank

Computer Graphics

#169

World Rank

#174

Historical Rank

Database

#5636

World Rank

#5849

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Tetsuya Suhara's Degrees

Doctorate Medicine Institute of Science Tokyo

Why Is Tetsuya Suhara Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tetsuya Suhara's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands (2007) (1854)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (1409)
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET (1997) (719)
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls (2013) (671)
Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain (2003) (594)
When Your Gain Is My Pain and Your Pain Is My Gain: Neural Correlates of Envy and Schadenfreude (2009) (437)
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET (2009) (302)
Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography (2007) (293)
Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders (2008) (254)
Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease (1997) (243)
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. (1995) (229)
Increased Binding of Peripheral Benzodiazepine Receptor in Alzheimer's Disease Measured by Positron Emission Tomography with [11C]DAA1106 (2008) (209)
Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation (2008) (206)
Dopamine D2 Receptors in the Insular Cortex and the Personality Trait of Novelty Seeking (2001) (204)
Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. (2002) (200)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (190)
A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) (188)
Age-related degeneration of corpus callosum measured with diffusion tensor imaging (2006) (186)
Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain (1994) (181)
Functional Brain Mapping of Monkey Tool Use (2001) (178)
Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. (2010) (172)
Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia (2001) (171)
No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET (2003) (167)
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies (2008) (164)
Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies (2017) (162)
Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain (2004) (157)
Differential Contributions of Prefrontal and Hippocampal Dopamine D1 and D2 Receptors in Human Cognitive Functions (2008) (156)
Age-related changes in human D1 dopamine receptors measured by positron emission tomography (2005) (154)
Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652 (2002) (151)
Pharmacokinetics and brain uptake of lactoferrin in rats. (2006) (150)
Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. (2004) (149)
Deficiency of Schnurri-2, an MHC Enhancer Binding Protein, Induces Mild Chronic Inflammation in the Brain and Confers Molecular, Neuronal, and Behavioral Phenotypes Related to Schizophrenia (2013) (142)
[(11)C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. (2003) (139)
Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor (2007) (138)
P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating (2011) (138)
Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment–dementia converters measured by positron emission tomography with [11C]DAA1106 (2012) (138)
Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. (2001) (136)
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. (2004) (134)
Men and women show distinct brain activations during imagery of sexual and emotional infidelity (2006) (128)
Brain activations during judgments of positive self-conscious emotion and positive basic emotion: pride and joy. (2008) (128)
Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology (2014) (126)
Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. (2004) (125)
Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. (2003) (124)
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders (2011) (123)
High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. (2003) (121)
Effects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI study (2005) (117)
Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. (1993) (117)
D1 dopamine receptor binding in mood disorders measured by positron emission tomography (2005) (106)
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys (2019) (105)
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia (2008) (104)
Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. (1999) (104)
A dose-finding study of duloxetine based on serotonin transporter occupancy (2006) (103)
Decreased 5-HT1A receptor binding in amygdala of schizophrenia (2004) (99)
Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy (2015) (97)
Memory and frontal lobe functions; possible relations with dopamine D2 receptors in the hippocampus (2007) (96)
Age-related decline of serotonin transporters in living human brain of healthy males. (2002) (95)
It’s Not My Fault: Postdictive Modulation of Intentional Binding by Monetary Gains and Losses (2012) (94)
PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 (2015) (94)
Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. (2006) (93)
Functional and structural synergy for resolution recovery and partial volume correction in brain PET (2009) (92)
Apathy correlates with prefrontal amyloid β deposition in Alzheimer's disease (2013) (91)
High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies (2020) (91)
Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age (1999) (91)
Mechanistic involvement of the calpain‐calpastatin system in Alzheimer neuropathology (2012) (90)
Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. (2006) (89)
A comparison of the high‐affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)‐PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation (2007) (87)
Lung as reservoir for antidepressants in pharmacokinetic drug interactions (1998) (87)
Glial cell-mediated deterioration and repair of the nervous system after traumatic brain injury in a rat model as assessed by positron emission tomography. (2010) (84)
In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil (2006) (83)
Regional cerebral blood flow changes associated with interoceptive awareness in the recovery process of anorexia nervosa (2006) (82)
[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR). (2003) (82)
Quantitative Analysis for Estimating Binding Potential of the Peripheral Benzodiazepine Receptor with [11C]DAA1106 (2007) (80)
Relationship Between Neuroticism Personality Trait and Serotonin Transporter Binding (2007) (80)
Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography (2008) (77)
Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I (2012) (76)
The Role of Extrastriatal Dopamine D2 Receptors in Schizophrenia (2006) (75)
Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with l-[β-11C]DOPA (2006) (75)
Reduced serotonin transporter binding in the insular cortex in patients with obsessive–compulsive disorder: A [11C]DASB PET study (2010) (75)
Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. (2000) (74)
Isolation and transplantation of dopaminergic neurons generated from mouse embryonic stem cells (2004) (74)
Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study (1998) (73)
Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study (2016) (73)
11C-AC-5216: A Novel PET Ligand for Peripheral Benzodiazepine Receptors in the Primate Brain (2007) (73)
Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons (2016) (70)
Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. (2008) (70)
Reproducibility of [11C]FLB 457 binding in extrastriatal regions (2001) (69)
Functional significance of central D1 receptors in cognition: beyond working memory (2012) (69)
PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation (2016) (67)
PET Mapping of Extrastriatal D2-like Dopamine Receptors in the Human Brain Using an Anatomic Standardization Technique and [11C]FLB 457 (1999) (66)
Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. (2006) (66)
In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. (2010) (66)
Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET (2009) (65)
In vivo binding properties of [carbonyl‐11C]WAY‐100635: Effect of endogenous serotonin (2001) (65)
β‐amyloid in lewy body disease is related to Alzheimer's disease‐like atrophy (2013) (64)
Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. (2010) (63)
Regional cerebral blood flow in depressed patients with white matter magnetic resonance hyperintensity (2003) (63)
Template-Based Method for Multiple Volumes of Interest of Human Brain PET Images (2002) (63)
Relation among dopamine D2 receptor binding, obesity and personality in normal human subjects (2001) (62)
Hierarchical order of coexisting pre- and postsynaptic forms of long-term potentiation at synapses in amygdala (2010) (62)
Quantitative magnetic resonance spectroscopy of schizophrenia: Relationship between decreased N‐acetylaspartate and frontal lobe dysfunction (2006) (62)
Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography (1993) (59)
Ten year progressive ventricular enlargement in schizophrenia: An MRI morphometrical study (2001) (58)
Effect of endogenous dopamine on extrastriatal [11C]FLB 457 binding measured by PET (2001) (58)
Electroconvulsive therapy decreases dopamine D₂receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [¹¹C]FLB 457. (2010) (56)
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. (2010) (55)
Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models (2018) (53)
Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats (2005) (53)
A Primary Role for Nucleus Accumbens and Related Limbic Network in Vocal Tics (2016) (52)
Phosphorylation and gene expression of p53 are not affected in human cells exposed to 2.1425 GHz band CW or W‐CDMA modulated radiation allocated to mobile radio base stations (2006) (52)
Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. (2004) (51)
Effects of sports participation on psychiatric symptoms and brain activations during sports observation in schizophrenia (2012) (50)
Dopamine D1 Receptors and Nonlinear Probability Weighting in Risky Choice (2010) (50)
Honesty mediates the relationship between serotonin and reaction to unfairness (2012) (50)
Dopamine D1 receptor number — a sensitive PET marker for early brain degeneration in Huntington's disease (2005) (50)
High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies (2020) (50)
Neural correlates of human virtue judgment. (2008) (49)
Quantitative Analysis of Norepinephrine Transporter in the Human Brain Using PET with (S,S)-18F-FMeNER-D2 (2008) (48)
Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. (2010) (47)
In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. (2018) (46)
Maternal immune activation by polyriboinosinic-polyribocytidilic acid injection produces synaptic dysfunction but not neuronal loss in the hippocampus of juvenile rat offspring (2010) (46)
Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. (2006) (46)
GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for α5 subunit (2008) (46)
Steroidogenic abnormalities in translocator protein knockout mice and significance in the aging male. (2018) (45)
Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635. (2010) (45)
An Alteration in the Lateral Geniculate Nucleus of Experimental Glaucoma Monkeys: In vivo Positron Emission Tomography Imaging of Glial Activation (2012) (43)
Relation between Presynaptic and Postsynaptic Dopaminergic Functions Measured by Positron Emission Tomography: Implication of Dopaminergic Tone (2011) (43)
Chronic Fluoxetine Selectively Upregulates Dopamine D1-Like Receptors in the Hippocampus (2012) (42)
Error Analysis for Quantification of [11C]FLB 457 Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain (2001) (42)
Contribution of Dopamine D1 and D2 Receptors to Amygdala Activity in Human (2010) (40)
Neural circuits in the brain that are activated when mitigating criminal sentences (2012) (40)
Serotonergic neurotransmission in the living human brain: A positron emission tomography study using [11C]dasb and [11C]WAY100635 in young healthy men (2011) (40)
The antipsychotic sultopride is overdosed--a PET study of drug-induced receptor occupancy in comparison with sulpiride. (2006) (40)
PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. (2019) (39)
Effects of the Antipsychotic Risperidone on Dopamine Synthesis in Human Brain Measured by Positron Emission Tomography with l-[β-11C]DOPA: A Stabilizing Effect for Dopaminergic Neurotransmission? (2009) (38)
Norepinephrine in the brain is associated with aversion to financial loss (2013) (38)
Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets (2007) (38)
Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone (2001) (38)
Altered brain activation by a false recognition task in young abstinent patients with alcohol dependence. (2007) (38)
In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease (2019) (37)
Guidelines for the content and format of PET brain data in publications and archives: A consensus paper (2020) (37)
Reduced gray matter volume of dorsal cingulate cortex in patients with obsessive–compulsive disorder: A voxel‐based morphometric study (2010) (36)
Estimation of Plasma IC50 of Donepezil for Cerebral Acetylcholinesterase Inhibition in Patients With Alzheimer Disease Using Positron Emission Tomography (2010) (35)
Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. (2009) (35)
Norepinephrine Transporter in Major Depressive Disorder: A PET Study. (2017) (35)
Selective Disruption of Inhibitory Synapses Leading to Neuronal Hyperexcitability at an Early Stage of Tau Pathogenesis in a Mouse Model (2020) (35)
Superiority illusion arises from resting-state brain networks modulated by dopamine (2013) (35)
Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2). (2013) (35)
Possible role of dopamine D1 receptors in schizophrenia (1997) (33)
Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2 (2010) (33)
Role of Ventral Striatal Dopamine D1 Receptor in Cigarette Craving (2007) (33)
Synthesis and evaluation of N-(5-fluoro-2-phenoxyphenyl)-N-(2-[(18)F]fluoromethoxy-d(2)-5-methoxybenzyl)acetamide: a deuterium-substituted radioligand for peripheral benzodiazepine receptor. (2005) (33)
Macaque prefrontal activity associated with extensive tool use (2002) (33)
Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants (2020) (33)
Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. (2002) (32)
Neuroimaging and Physiological Evidence for Involvement of Glutamatergic Transmission in Regulation of the Striatal Dopaminergic System (2009) (32)
Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2 (2017) (32)
Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization (1999) (32)
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain. (2006) (32)
Muscarinic cholinergic receptors in human narcolepsy (1998) (31)
Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA (2012) (31)
Progressive changes of pre‐ and post‐synaptic dopaminergic biomarkers in conscious MPTP‐treated cynomolgus monkeys measured by positronemission tomography (2007) (31)
Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine (2006) (31)
Visualization of α5 subunit of GABAA/benzodiazepine receptor by [11C]Ro15‐4513 using positron emission tomography (2003) (31)
Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [11C]PiB PET (2016) (31)
Quantitative Analysis for Estimating Binding Potential of the Brain Serotonin Transporter with [11C]McN5652 (2002) (31)
Quantification of Central Substance P Receptor Occupancy by Aprepitant Using Small Animal Positron Emission Tomography (2015) (30)
In Vivo SPECT Imaging of Amyloid-β Deposition with Radioiodinated Imidazo[1,2-a]Pyridine Derivative DRM106 in a Mouse Model of Alzheimer's Disease (2014) (30)
Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET (1995) (30)
Enhanced activation in the extrastriate body area by goal‐directed actions (2008) (30)
PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. (1996) (30)
Dementia with Lewy bodies can be well‐differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity—a [11C]MP4A PET study (2015) (29)
No age-related changes in human benzodiazepine receptor binding measured by PET with [11C]Ro 15-4513 (1993) (29)
In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy (2019) (29)
Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA. (2006) (28)
Relationship between baseline cerebral blood flow and vascular responses to changes in PaCO2 measured by positron emission tomography in humans: implication of inter‐individual variations of cerebral vascular tone (2008) (28)
Total body 100-mGy X-irradiation does not induce Alzheimer's disease-like pathogenesis or memory impairment in mice (2013) (28)
Effect of desipramine on dopamine receptor binding in vivo. (1990) (28)
Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[&bgr;-11C]DOPA (2006) (27)
Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau (2014) (27)
Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM (2012) (27)
In vivo binding of [11C]Ro15-4513 in human brain measured with PET (1992) (26)
Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor (2021) (26)
Amyloid imaging with [18F]florbetapir in geriatric depression: early‐onset versus late‐onset (2015) (26)
Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure. (2005) (26)
Synthesis and preliminary PET study of the 5‐HT7 receptor antagonist [11C]DR4446 (2002) (26)
Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres (2019) (26)
No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. (2009) (26)
Carbon-11-methionine positron emission tomography imaging of chordoma (2004) (25)
[11C]Methionine Positron Emission Tomography and Survival in Patients with Bone and Soft Tissue Sarcomas Treated by Carbon Ion Radiotherapy (2004) (25)
Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia (2017) (25)
Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer’s disease (2018) (25)
Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET with 11C-AC-5216 (2009) (25)
Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models (2010) (25)
Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors (2016) (25)
Mobile phone base station radiation does not affect neoplastic transformation in BALB/3T3 cells (2008) (24)
Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET (2016) (24)
Clozapine can induce high dopamine D2 receptor occupancy in vivo (2002) (24)
Signaling Incentive and Drive in the Primate Ventral Pallidum for Motivational Control of Goal-Directed Action (2018) (24)
Functional network in the prefrontal cortex during episodic memory retrieval (2005) (24)
Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex (2003) (23)
A prodrug of NMDA/glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog. (2001) (23)
Syntheses and pharmacological evaluation of two potent antagonists for dopamine D4 receptors: [11C]YM-50001 and N-[2-[4-(4-Chlorophenyl)-piperizin-1-yl]ethyl]-3-[11C]methoxybenzamide. (2002) (23)
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging (2015) (23)
Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations (2006) (23)
Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂. (2014) (23)
Chronic lithium chloride injection increases glucocorticoid receptor but not mineralocorticoid receptor mRNA expression in rat brain (2000) (23)
Characterization of 1‐(2‐[18F]fluoro‐3‐pyridyl)‐4‐(2‐isopropyl‐1‐oxo‐ isoindoline‐5‐yl)‐5‐methyl‐1H‐1,2,3‐triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains (2012) (23)
Neural basis of negativity bias in the perception of ambiguous facial expression (2017) (23)
First prototyping of a dedicated PET system with the hemisphere detector arrangement (2019) (23)
Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride (2013) (23)
PET imaging of colony-stimulating factor 1 receptor: A head-to-head comparison of a novel radioligand, 11C-GW2580, and 11C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey (2021) (22)
PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson’s Disease (2012) (22)
Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density (2016) (22)
Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor. (2013) (21)
Fronto-parieto-cerebellar interaction associated with intermanual transfer of monkey tool-use learning (2003) (21)
Brain and whole body distribution ofN-isopropyl-4-iodoamphetamine (I-123) in humans: Comparison of radiopharmaceuticals marketed by different companies in Japan (2006) (21)
Measurement of glycine binding site of N‐methyl‐d‐asparate receptors in living human brain using 4‐acetoxy derivative of L‐703,717, 4‐acetoxy‐7‐chloro‐3‐[3‐(4‐[11c] methoxybenzyl) phenyl]‐2(1H)‐quinolone (AcL703) with positron emission tomography (2007) (21)
Effects of endogenous agonists, glycine and D‐serine, on in vivo specific binding of [11C]L‐703,717, a PET radioligand for the glycine‐binding site of NMDA receptors (2003) (21)
Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model (2013) (21)
Quantitative PET Analysis of the Dopamine D2 Receptor Agonist Radioligand 11C-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain (2009) (21)
Abnormal axon guidance signals and reduced interhemispheric connection via anterior commissure in neonates of marmoset ASD model (2019) (21)
Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184 (2014) (20)
Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB (2014) (20)
In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. (2010) (20)
Chemogenetic dissection of the primate prefronto-subcortical pathways for working memory and decision-making (2021) (20)
Synthesis and evaluation of 3-(4-chlorobenzyl)-8-[11C]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one: a PET tracer for imaging sigma1 receptors (2002) (20)
Development of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptors. (2015) (20)
PET Quantification of the Norepinephrine Transporter in Human Brain with (S,S)-18F-FMeNER-D2 (2016) (20)
Laterality and aging of thalamic subregions measured by diffusion tensor imaging (2007) (19)
Development of 1-N-11C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan (2015) (19)
In vivo mapping of substance P receptors in brains of laboratory animals by high‐resolution imaging systems (2007) (19)
Chronic repetitive transcranial magnetic stimulation failed to change dopamine synthesis rate: Preliminary L‐[β‐11C]DOPA positron emission tomography study in patients with depression (2010) (18)
In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response (2002) (18)
Vocalizations associated with anxiety and fear in the common marmoset (Callithrix jacchus) (2014) (18)
Changes in central 5-HT1A receptor binding in mesial temporal epilepsy measured by positron emission tomography with [11C]WAY100635 (2007) (18)
A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors (2017) (18)
Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel‐based analysis for entorhinal cortex atrophy (2015) (18)
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain. (2007) (17)
Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. (2017) (17)
Classification of Clinically Diagnosed Alzheimer's Disease Associated with Diabetes Based on Amyloid and Tau PET Results. (2019) (17)
Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457 (2012) (16)
Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[&bgr;-11C]DOPA and [18F]FE-PE2I in humans (2014) (16)
Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors (2016) (16)
A new method to quantify tau pathologies with 11C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter (2016) (16)
Relation between Dopamine Synthesis Capacity and Cell-Level Structure in Human Striatum: A Multi-Modal Study with Positron Emission Tomography and Diffusion Tensor Imaging (2014) (16)
Regulation of Anxiety and Depression by Mitochondrial Translocator Protein-Mediated Steroidogenesis: the Role of Neurons (2020) (16)
Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features (2019) (16)
Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula (2018) (15)
Mapping of central dopamine synthesis in man, using positron emission tomography with l-[β-11C]DOPA (2007) (15)
Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. (2011) (15)
Binding of Dopamine D1 Receptor and Noradrenaline Transporter in Individuals with Autism Spectrum Disorder: A PET Study. (2020) (15)
Enhancing Multi-Center Generalization of Machine Learning-Based Depression Diagnosis From Resting-State fMRI (2019) (15)
PRECLINICAL STUDY: Different effects of chronic phencyclidine on brain‐derived neurotrophic factor in neonatal and adult rat brains (2006) (15)
Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter. (2009) (15)
Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D2 receptors (2017) (15)
Distinct binding of amyloid imaging ligands to unique amyloid‐β deposited in the presubiculum of Alzheimer's disease (2015) (15)
In vivo and in vitro imaging of I2 imidazoline receptors in the monkey brain (2011) (15)
Simultaneous quantification of two brain functions with dual tracer injection in PET dynamic study (2004) (15)
Quantitative and Noninvasive Assessment of Prenatal X-Ray-Induced CNS Abnormalities Using Magnetic Resonance Imaging (2011) (14)
Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report (2016) (14)
In Vivo PET Measurements with [11C]PE2I to Evaluate Fetal Mesencephalic Transplantations to Unilateral 6-OHDA-Lesioned Rats (2005) (14)
Neuroticism Associates with Cerebral in Vivo Serotonin Transporter Binding Differently in Males and Females (2017) (14)
19F‐magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate (2002) (14)
Development of N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives as PET radioligands for the glycine-binding site of NMDA receptors. (2009) (14)
Hydration level is an internal variable for computing motivation to obtain water rewards in monkeys (2012) (14)
Regional heterogeneity and age-related change in sub-regions of internal capsule evaluated by diffusion tensor imaging (2010) (14)
Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia (2005) (14)
In-vivo PET imaging of inducible D2R reporter transgene expression using [11C]FLB 457 as reporter probe in living rats (2005) (14)
Alterations in the expressions of mRNA for GDNF and its receptors in the ventral midbrain of rats exposed to subchronic phencyclidine. (2004) (13)
Development of the helmet-chin PET prototype (2015) (13)
Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia. (2018) (13)
Quantitative assessment of central nervous system disorder induced by prenatal X‐ray exposure using diffusion and manganese‐enhanced MRI (2012) (13)
Quantitative Analysis of NK1 Receptor in the Human Brain Using PET with 18F-FE-SPA-RQ (2008) (13)
[11C]metaraminol, a false neurotransmitter: preparation, metabolite studies and positron emission tomography examination in monkey. (1996) (13)
Tau oligomers as potential targets for early diagnosis of tauopathy. (2014) (13)
Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine. (1991) (13)
[11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain (2016) (13)
Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography (1994) (13)
Functional Organization of Monkey Brain for Abstract Operation (2007) (12)
Association between Brain and Plasma Glutamine Levels in Healthy Young Subjects Investigated by MRS and LC/MS (2019) (12)
Synthesis and biological evaluation of novel radioiodinated imidazopyridine derivatives for amyloid-β imaging in Alzheimer's disease. (2014) (12)
Seizure frequency and bilateral temporal abnormalities: a proton magnetic resonance spectroscopy of temporal lobe epilepsy (2000) (12)
Measurement of dopamine D2 receptors in living human brain using [11C]raclopride with ultra-high specific radioactivity. (2010) (12)
Chemogenetic activation of nigrostriatal dopamine neurons in freely moving common marmosets (2021) (12)
Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with 18F-FEDAA1106 (2008) (12)
Development of 123I-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding. (1996) (12)
Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors. (2010) (12)
Synthesis of 11C-labelled bis(phenylalkyl)amines and their in vitro and in vivo binding properties in rodent and monkey brains. (2004) (12)
In vivo evaluation of cellular activity in αCaMKII heterozygous knockout mice using manganese-enhanced magnetic resonance imaging (MEMRI) (2013) (12)
Role of left superior temporal gyrus during name recall process: An event-related fMRI study (2008) (12)
Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with 18F-FE-PE2I (2015) (12)
Correlation between decreased motor activity and dopaminergic degeneration in the ventrolateral putamen in monkeys receiving repeated MPTP administrations: A positron emission tomography study (2012) (11)
A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies (2010) (11)
Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel. (2008) (11)
Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine‐induced behavior and c‐fos mRNA expression in the brain (2001) (11)
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET) (1997) (11)
Dopamine D 1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study (11)
A positron‐emitter labeled glycineB site antagonist, [11C]L‐703,717, preferentially binds to a cerebellar NMDA receptor subtype consisting of GluR ϵ3 subunit in vivo, but not in vitro (2002) (11)
Striatal and extrastriatal dopamine D 2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study (2012) (10)
Muscarinic receptor occupancy by biperiden in living human brain. (1999) (10)
A high-yield automated radiosynthesis of the alpha-7 nicotinic receptor radioligand [18F]NS10743. (2015) (10)
A migration case of Kii amyotrophic lateral sclerosis/parkinsonism dementia complex with the shortest stay in the endemic area and the longest incubation to develop the disease (2017) (10)
Differentiation Between Dementia With Lewy Bodies And Alzheimer’s Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study (2019) (10)
Detection of Alzheimer’s disease-related neuroinflammation by a PET ligand selective for glial versus vascular translocator protein (2021) (10)
In vivo positron emission tomography imaging of mitochondrial abnormalities in a mouse model of tauopathy (2020) (10)
Molecular imaging of dementia (2012) (10)
Nitric Oxide Signaling Exerts Bidirectional Effects on Plasticity Inductions in Amygdala (2013) (10)
Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy (2021) (10)
Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain (2012) (10)
Effects of menopause on brain structural changes in schizophrenia (2013) (10)
Swim stress alters in vivo binding of [3H]N-methylspiperone (1991) (10)
Excess tau PET ligand retention in elderly patients with major depressive disorder (2020) (9)
Microglial Activation During Pathogenesis of Tauopathy in rTg4510 Mice: Implications for the Early Diagnosis of Tauopathy. (2018) (9)
Neuroimaging in dementia: in vivo amyloid imaging. (2008) (9)
Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid-β imaging in mouse model of Alzheimer's disease (2014) (9)
Low‐dose total‐body carbon‐ion irradiations induce early transcriptional alteration without late Alzheimer's disease‐like pathogenesis and memory impairment in mice (2014) (9)
Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease. (2018) (9)
Chemogenetic sensory fMRI reveals behaviorally relevant bidirectional changes in primate somatosensory network (2021) (9)
Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457 (2008) (9)
Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology. (2015) (9)
Effects of image reconstruction algorithm on neurotransmission PET studies in humans: Comparison between filtered backprojection and ordered subsets expectation maximization (2006) (9)
In Vivo Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line (2017) (9)
Metabolite analysis of [11C]Ro15-4513 in mice, rats, monkeys and humans. (2003) (8)
Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain (2017) (8)
Effects of cocaine on [11C]norepinephrine and [11C]β-CIT uptake in the primate peripheral organs measured by PET (1996) (8)
Monkey brain areas underlying remote‐controlled operation (2004) (8)
Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects (2010) (8)
Extrastriatal dopamine D2 receptor occupancy in olanzapine-treated patients with schizophrenia (2010) (8)
7Li 2D CSI of human brain on a clinical scanner (2001) (8)
Emergence of realism: Enhanced visual artistry and high accuracy of visual numerosity representation after left prefrontal damage (2014) (8)
Development of radioligands for the dopamine transporter (1996) (8)
A possible serologic biomarker for maternal immune activation-associated neurodevelopmental disorders found in the rat models (2016) (8)
Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by 11C Ro15-4513 using positron emission tomography. (2003) (8)
In vivo tau PET imaging using [11C]PBB3 in Alzheimer’s disease and non-Alzheimer’s disease tauopathies (2014) (8)
Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine (2002) (7)
No inhibitory effect on P-glycoprotein function at blood–brain barrier by clinical dose of clarithromycin: a human PET study with [11C]verapamil (2010) (7)
Decreased 5-HT 1A Receptor Binding in Amygdala of (2004) (7)
Increased binding of 5-HT1A receptors in a dissociative amnesic patient after the recovery process (2014) (7)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (7)
Quantitative analyses of [11C]Ro15-4513 binding to subunits of GABAA/benzodiazepine receptor in the living human brain (2009) (7)
In vivo imaging of neuroinflammation in Alzheimer's disease (2016) (7)
Synthesis and evaluation of 18F- and 11C-labelled 9,10-ethanobenzo[b]quinolizinium derivatives for imaging of the NMDA receptor at the TCP-binding site (2000) (7)
Phosphorous-31 magnetic resonance spectroscopy of cervical cancer using transvaginal surface coil. (2005) (7)
Pharmacological and Genetic Inhibition of Translocator Protein 18 kDa Ameliorated Neuroinflammation in Murine Endotoxemia Model. (2020) (7)
[An improved automated synthesis and in vivo evaluation of PET radioligand for serotonin re-uptake sites: [11C]McN5652X]. (1996) (7)
Effect of radiolabeled metabolite elimination from the brain on the accuracy of cerebral enzyme activity estimation using positron emission tomography with substrate tracers (2011) (7)
[Imaging blood-brain barrier function by using positron emission tomography to evaluate drug penetration into the brain]. (2013) (6)
Imaging of Neuronal Activity in Awake Mice by Measurements of Flavoprotein Autofluorescence Corrected for Cerebral Blood Flow (2018) (6)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (1994) (6)
Relation between cortical dopamine D2 receptor occupancy and suppression of conditioned avoidance response in non‐human primate (2004) (6)
Neonatal treatment with l-name (ng-nitro-l-arginine methyl ester) attenuates stereotyped behavior induced by acute methamphetamine but not development of behavioral sensitization to methamphetamine (2000) (6)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (6)
Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy (2018) (6)
A Small-Animal Pharmacokinetic/Pharmacodynamic PET Study of Central Serotonin 1A Receptor Occupancy by a Potential Therapeutic Agent for Overactive Bladder (2013) (6)
Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation (2020) (6)
Behavioral / Systems / Cognitive Dopamine D 1 Receptors and Nonlinear Probability Weighting in Risky Choice (2010) (6)
High-Contrast PET Imaging of Vasopressin V1B Receptors with a Novel Radioligand, 11C-TASP699 (2017) (6)
Animal models of tauopathies (2006) (5)
Correction of head movement by frame-to-frame image realignment for receptor imaging in positron emission tomography studies with [11C]raclopride and [11C]FLB 457 (2019) (5)
Synthesis and characterization of 11 C-labeled benzyl amidine derivatives as PET radioligands for GluN2B subunit of the NMDA receptors. (2018) (5)
Longitudinal [11C]PIB PET study in healthy elderly persons, patients with mild cognitive impairment, and Alzheimer's disease (2011) (5)
Identifying melancholic depression biomarker using whole-brain functional connectivity (2017) (5)
Biodistribution and radiation dosimetry in humans of [¹¹C]FLB 457, a positron emission tomography ligand for the extrastriatal dopamine D₂ receptor. (2014) (5)
[Pulmonary kinetics of 13N-ammonia in smoking subjects--a quantitative study using dynamic PET]. (1992) (5)
IMAGING OF TAU PATHOLOGY IN PATIENTS WITH NON-ALZHEIMER'S DISEASE TAUOPATHIES BY [11C]PBB3-PET (2014) (5)
Histamine H3 receptor density is negatively correlated with neural activity related to working memory in humans (2018) (5)
Diagnostic Utility and Clinical Significance of Tau PET imaging with [11C]PBB3 in Diverse Tauopathies (2015) (5)
In vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies (2009) (5)
Comparative evaluation of two serotonin transporter ligands in the human brain: [(11)C](+)McN5652 and [(11)C]cyanoimipramine. (2002) (4)
In vitro evidence for competitive tspo binding of the imaging biomarker candidates vinpocetine and two iodinated daa1106 analogues in post mortem autoradiography experiments on whole hemisphere human brain slices (2009) (4)
Recurrent hyperperfusion in the right orbitofrontal cortex in obsessive–compulsive disorder (2008) (4)
Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments. (2016) (4)
Synthesis and evaluation of 3-(4-chlorobenzyl)-8-[11C]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one: a PET tracer for imaging sigma(1) receptors. (2002) (4)
In vivo PET imaging of the behaviorally active designer receptor in macaque monkeys (2014) (4)
Single caudate neurons encode temporally discounted value for formulating motivation for action (2020) (4)
Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease (2020) (4)
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients (2022) (4)
Publisher Correction: Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants (2020) (4)
Beyond PIB: the next generation of amyloid‐imaging ligands (2008) (4)
In vivo visualization of tau pathology (2013) (4)
Dynamic alterations in the central glutamatergic status following food and glucose intake: in vivo multimodal assessments in humans and animal models (2021) (4)
Effects of the reference tissue setting on the parametric image of 11C-WAY 100635 (2007) (4)
[Effect of aging on in vivo binding of 11C-N-methylspiperone in living human frontal cortex]. (1991) (3)
TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor (2016) (3)
Effect of Cooperation Level of Group on Punishment for Non-Cooperators: A Functional Magnetic Resonance Imaging Study (2012) (3)
Neuroimaging in psychiatry: Current methods and future direction (2016) (3)
Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy (2022) (3)
Inverse correlation between body mass index and serotonin transporter binding in human brain: A [11C]DASB PET study (2008) (3)
Visual evaluation of kinetic characteristics of PET probe for neuroreceptors using a two-phase graphic plot analysis (2017) (3)
D1- and D2-like receptors differentially mediate the effects of dopaminergic transmission on cost/benefit evaluation and motivation in monkeys (2021) (3)
Radiosynthesis and in vivo Evaluation of Carbon‐11 (2S)‐3‐(1H‐Indol‐3‐yl)‐2‐{[(4‐methoxyphenyl)carbamoyl]amino}‐N‐{[1‐(5‐methoxypyridin‐2‐yl)cyclohexyl]methyl}propanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation (2016) (3)
[Distribution and function of dopamine D1, D2 receptor]. (2007) (3)
AGE-RELATED WHITE MATTER PATHOGENESIS IN A MOUSE MODEL OF TAUOPATHY (2014) (3)
High‐Contrast Imaging of α‐Synuclein Pathologies in Living Patients with Multiple System Atrophy (2022) (3)
An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography (2005) (3)
Synthesis and brain regional distribution of [11C]NPS 1506 in mice and rat: an N-methyl-D-aspartate (NMDA) receptor antagonist. (2003) (3)
New radioligands for pet-examination of central muscarinic receptors (1994) (3)
Evaluation of [11C]oseltamivir uptake into the brain during immune activation by systemic polyinosine-polycytidylic acid injection: a quantitative PET study using juvenile monkey models of viral infection (2014) (3)
PET applications in animal models of neurodegenerative and neuroinflammatory disorders. (2012) (3)
Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy (2022) (3)
Monkey brain activity modulated by reward preferences: A positron emission tomography study (2009) (3)
Age correlates with cortical acetylcholinesterase decline in Alzheimer's disease patients: A PET study (2012) (3)
Quantitative Measurement of Acetylcholinesterase Activity in Living Human Brain Using a Radioactive Acetylcholine Analog and Dynamic PET (1998) (3)
[Pathophysiology of mood disorders and the therapy]. (2002) (3)
PRECLINICAL AND CLINICAL CHARACTERIZATION OF 18F-PM-PBB3, A PET LIGAND FOR DIVERSE TAU PATHOLOGIES (2018) (2)
IN VIVO PET IMAGING OF MITOCHONDRIAL ABNORMALITIES IN A MOUSE MODEL OF TAUOPATHY (2017) (2)
[Evaluation of imaging biomarker by transgenic mouse models]. (2009) (2)
Genetically targeted reporter imaging of deep neuronal network in the mammalian brain (2020) (2)
Quantification of Neuroreceptors and Neurotransporters (2012) (2)
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699 (2021) (2)
IN VIVO TRACKING OF TAU PATHOLOGIES WITH 18F-PM-PBB3 (18F-APN-1607) PET IN AD AND DIVERSE NON-AD TAUOPATHIES (2019) (2)
In vivo visualization of tau pathology in Alzheimer's disease patients by [11C]PBB3-PET (2013) (2)
THE ASSOCIATION BETWEEN AB AND TAU ACCUMULATIONS AND ITS INFLUENCE ON CLINICAL FEATURES IN AGING AND ALZHEIMER’S DISEASE SPECTRUM BRAINS: [11C]PBB3 PET STUDY (2016) (2)
Neural damage due to temporal lobe epilepsy: Dual‐nuclei (proton and phosphorus) magnetic resonance spectroscopy study (2004) (2)
[11C]AC-5216: RADIOSYNTHESIS AND EVALUATION ASA NOVEL POSITRON EMISSION TOMOGRAPHY LIGAND FOR PERIPHERAL-TYPE BENZODIAZEPINE RECEPTORS IN PRIMATE BRAIN (2007) (2)
Resting-state brain activity can predict target-independent aptitude in fMRI-neurofeedback training (2021) (2)
Tracking tau fibrillogenesis and consequent primary phagocytosis of neurons mediated by microglia in a living tauopathy model (2020) (2)
Relationship between regional gray matter volumes and dopamine D2 receptor and transporter in living human brains (2021) (2)
Use of human methylation arrays for epigenome research in the common marmoset (Callithrix jacchus) (2017) (2)
The necessary parameters for estimating the time-course of receptor occupancy. (2005) (2)
Central Nervous System Drug Evaluation Using Positron Emission Tomography (2011) (2)
Localized Accumulation of Tau without Amyloid-Beta in Aged Brains Measured with [11C]PBB3 and [11C]Pib Positron Emission Tomography (2017) (2)
[Alzheimer's disease and microglia]. (2011) (2)
Effect of sedative drugs upon receptor binding in vivo. (1992) (2)
[11C]PBB3 PET VISUALIZES TAU AGGREGATES IN PATIENTS WITH FTDP-17 MAPT GENE MUTATION (2016) (2)
In vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies (2009) (2)
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457 (2021) (2)
Positron emission tomography inter-scanner differences in dopamine D2 receptor binding measured with [11C]FLB457 (2010) (2)
In vivo visualization of tau pathology in Alzheimer's disease patients by [11c]PBB3-PET (2013) (2)
Association between Striatal Subregions and Extrastriatal Regions in Dopamine D1 Receptor Expression: A Positron Emission Tomography Study (2012) (2)
Initial clinical test of the first Helmet-Chin PET prototype for highly sensitive brain imaging (2016) (2)
Quantification of peripheral benzodiazepine receptors using a new aryloxyanilide based ligand [11C]PBR28 in monkey and human (2007) (2)
Neuromolecular basis of faded perception associated with unreality experience (2018) (2)
Chemogenetic Disconnection between the Orbitofrontal Cortex and the Rostromedial Caudate Nucleus Disrupts Motivational Control of Goal-Directed Action (2022) (2)
S-52-2 Imaging of the brain serotonin system (1996) (2)
THE ASSOCIATION BETWEEN Aβ AND TAU ACCUMULATIONS AND ITS INFLUENCE ON CLINICAL FEATURES IN AGING AND ALZHEIMER’S DISEASE SPECTRUM BRAINS: [11C]PBB3 PET STUDY (2016) (2)
PET-based classification of corticobasal syndrome. (2022) (2)
Brain 5-HT2A receptor binding and its neural network related to behavioral inhibition system (2022) (2)
[Receptor occupancy and antipsychotic drug action measured by PET and SPECT]. (2001) (1)
Age correlates with cortical acetylcholinesterase decline in Alzheimer's disease patients: A PET study (2012) (1)
SPECT IMAGING FOR AMYLOID PLAQUES WITH A NOVEL RADIOIODINATED LIGAND IN AN ALZHEIMER'S DISEASE MODEL (2014) (1)
Noninvasive k 3 estimation method for slow dissociation PET ligands: application to ( 11 C) (2013) (1)
Preparation of acute living hippocampal slice from common marmoset (Callithrix jacchus) for synaptic function analysis (2012) (1)
O-12-6 Petstudies of D1 and D2 dopamine receptors in schizophrenic patients (1996) (1)
Quantitative analysis of norepinephrine transporter binding in human brain using PET with (S,S)-[18F]FMeNER-D2 (2008) (1)
Evaluation of error on parameter estimates in the quantitative analysis of receptor studies with positron emission tomography (2005) (1)
729. Delayed-Onset Psychosis following TBI is Associated with Tau Depositions in the Neocortex but Not with β-Amyloid Depositions: A Pet Study with [11C]PBB3 and [11C]PiB (2017) (1)
D1Doparnine Receptor Binding in Mood Disorders Measured by PET (1992) (1)
Estimation of time course of dopamine D2 receptor occupancy from plasma pharmacokinetics of antipsychotics (2003) (1)
The high-affinity peripheral benzodiazepine receptor ligand [C-11]DAA1106 results in improved delineation of neuroinflammatory lesions in a rodent model of disease compared to [C-11]PK11195 (2006) (1)
74-8 Direct 2D-spectroscopic imaging of lithium in patients (1997) (1)
ANTI-INFLAMMATORY EFFECT OF TSPO LIGAND IN MOUSE MODEL OF TAUOPATHY (2017) (1)
Effects of smoking on the lung accumulation of [11C]McN5652 (2007) (1)
emission tomography ligand for the extrastriatal dopamine D 2 receptor (2014) (1)
A genetically targeted reporter for PET imaging of deep neuronal circuits in mammalian brains (2021) (1)
[Molecular imaging of psychiatric disorders]. (2007) (1)
Long‐term suppression of methamphetamine‐induced c‐Fos expression in rat striatum by the injection of c‐fos antisense oligodeoxynucleotides absorbed in water‐absorbent polymer (2004) (1)
Dr. Yasuno and Colleagues Reply (2004) (1)
TAU PET IMAGING IN ANIMAL MODELS AND HUMANS (2014) (1)
D1- and D2-like receptors differentially mediate the effects of dopaminergic transmission on cost–benefit evaluation and motivation in monkeys (2021) (1)
Resting-state functional connectivity relates to interindividual variations in positive memory (2021) (1)
Quantitative analysis of dopamine D2 receptor binding in human brain using PET with an agonist radioligand [11C]MNPA (2008) (1)
Amyloid-Negative Dementia in the Elderly is Associated with High Accumulation of Tau in the Temporal Lobes (2019) (1)
Compensation, Insurance, and Management of Injuries in Investigator-Initiated Clinical Trials in Japan (2016) (1)
AMYLOID AND TAU PET FINDINGS IN DIABETES-RELATED DEMENTIA (2016) (1)
Evaluation of error on parameter estimates in the analysis of receptor studies with positron emission tomography (2005) (1)
Effect of L-dopa and reserpine on in vivo binding of (3H)-SCH 23390 and (3H)-N-methylspiperone. (1991) (1)
Measurement of glycine binding site of N-methyl-d-aspartate (NMDA) receptors in living human brain using 4-Acetoxy derivative of l-703,717, 4-Acetoxy-7-chloro-3-[3-(4-[11C] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with PET (2006) (1)
[Pathophysiology and treatment of depression: a review of PET imaging of serotonin transporter. (2007) (1)
Hippocampal dopamine D2 receptors are involved in memory and frontal lobe functions (2006) (1)
Preparation and Examination of Labelled Stereoisomers in Vivo by Pet (1995) (1)
TASP 0434299 : A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V 1 B Receptor (2016) (1)
A database of the intraindividual presynaptic serotonin transporter and postsynaptic serotonin 1A receptor functions: A PET study with [C-11]WAY-100635 and [C-11]DASB (2008) (1)
[Imaging of glial cells by positron-emitted peripheral benzodiazepine receptor ligands]. (2006) (1)
Quantitative analysis of tau pathology in human brain using PET with [C-11]PBB3 (2015) (1)
Behavioral characteristics of low-motivation and its relation to serotonin in a primate model of depression (2010) (1)
Animal models of tauopathies. (2006) (1)
Influence of O-Methylated Metabolite Penetrating the Blood–Brain Barrier to Estimation of Dopamine Synthesis Capacity in Human L-[β-11C]DOPA PET (2014) (1)
Total-body low-dose irradiation of mice induces neither learning disability and memory impairment in Morris water maze test nor Alzheimer's disease-like pathogensis in the brain (2014) (1)
Alpha-CaMKII deficiency causes dysregulated behaviours and immature dentate gyrus (2007) (0)
Poster #162 EFFECT OF SPORTS PARTICIPATION ON BRAIN ACTIVATIONS DURING SPORTS OBSERVATION IN SCHIZOPHRENIA (2012) (0)
Measurement of Striatal Dopamine Release Induced by Neuropsychological Stimulation in Positron Emission Tomography With Dual Injections of [11C]Raclopride (2022) (0)
A new graphic plot method for determination of neuroreceptor binding in PET studies (2008) (0)
The 42nd Annual Meeting of The Japanese Society of Neuroradiology, 15–16 February 2013, Kokura, Japan (2013) (0)
Molecular imaging for motivational function and dysfunction (2011) (0)
PET measurement of brain acetylcholinesterase activities in cortex and subcortical areas (2016) (0)
Correction: Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain (2018) (0)
In-vivo Imaging of Neuronal Differentiation and Function of Intracranially Implanted Induced Pluripotent Stem Cells (iPSCs) Using A Designer Receptor Exclusively Activated by A Designer Drug (DREADD) (2014) (0)
NEUROPROTECTIVE ACTION OF SINGLE DOSE DEPRENYL AGAINST MPTP-INDUCED PARKINSONISM IN COMMON MARMOSETS (2005) (0)
PET Quantification in Molecular Brain Imaging Taking into Account the Contribution of the Radiometabolite Entering the Brain (2016) (0)
AMYLOID AND TAU IMAGING IN PATIENTS WITH POSTERIOR CORTICAL ATROPHY (2018) (0)
Effects of second-generation antipsychotic drug on dopamine synthesis in human brain measured by PET with L-[C-11]DOPA (2009) (0)
Selective dysfunction of fast-spiking inhibitory interneurons and disruption of perineuronal nets in a tauopathy mouse model (2023) (0)
PM371. Measurement of genomic copy number and DNA methylation levels of LINE-1 in the brains of poly(I:C) mouse model (2016) (0)
[Molecular neuroimaging in schizophrenia]. (2013) (0)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (2004) (0)
Contribution of Dopamine D1 and D2 Receptors to Amygdala Activity (2009) (0)
TRANSLOCATOR PROTEIN AS A THERAPEUTIC TARGET FOR ALZHEIMER`S DISEASE (2015) (0)
Evaluation of hippocampal degeneration after prenatal radiation exposure using Manganese-enhanced MRI ( MEMRI ) (2008) (0)
Synthesis and evaluation of C‐11 labeled analog of CP‐101, 606 as a pet tracer for NR2B‐containing NMDA receptors (2001) (0)
Superiority of Implicit Self-evaluation and Resting-State Functional Connectivity Network (2019) (0)
Multimodal database of dopaminergic neurotransmission functions in substantia nigra measured by MRI and PET (2016) (0)
Neural network of superiority illusion predicts the level of dopamine in striatum (2022) (0)
[In vivo evaluation of expressed protein function by PET]. (2005) (0)
Cortical amyloid deposition in Lewy body diseases with dementia demonstrated by PET (2009) (0)
[11C]PBB3 PET detects tau pathology in corticobasal syndrome and progressive supranuclear palsy. (2015) (0)
Regional differences in occupancy of dopamine D2 receptors by second-generation antipsychotics in humans measured using PET (2008) (0)
Neural correlates of transmission from lexical-semantic to lexical-phonological stages during name recall: An event-related fMRI study (2008) (0)
PET quantification of binding of a novel tau radioligand, 18F-AM-PBB3, in consideration of time-dependent changes in its plasma free fraction (2017) (0)
[Molecular imaging for pharmacodynamics of psychotropic drugs]. (2007) (0)
Contents of The American Journal of Psychiatry (2003) (0)
INVESTIGATING THE LINK BETWEEN PATHOLOGICAL TAU ACCUMULATION, NEUROINFLAMMATION AND BRAIN ATROPHY IN A MODEL OF TAUOPATHY (2016) (0)
Semi-automatic volumetrics system to parcellate ROI on neocortex (2002) (0)
2.021 DEMENTIA WITH LEWY BODIES CAN BE WELL-DIFFERENTIATED FROM ALZHEIMER'S DISEASE BY MEASUREMENT OF BRAIN ACETYLCHOLIN ESTERASE ACTIVITY BY PET (2012) (0)
Evaluation of Optimal Scan Time by Bootstrap Approach for Quantitative Analysis in PET Receptor Study (2006) (0)
[PET (positron emission tomography) research on schizophrenia]. (2006) (0)
Development of therapies and monitoring against tauopathies with dementia (2010) (0)
Utility of tau imaging probe pbb3 on a mouse model of tauopathy (2015) (0)
In vivo detection of amyloid deposition using [11C]AZD2184 PET (2012) (0)
Measurement of changes in endogenous serotonin level by positron emission tomography with [18F]altanserin (2021) (0)
Imaging extra-striatal dopamine D2 receptors in a maternal immune activation rat model (2022) (0)
Selective autophagy in neurons and its involvement in the tau pathogenesis (2011) (0)
Possible value of Positron emission tomography for early diagnosis of Alzheimer disease (2003) (0)
Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy (2021) (0)
Does a single low dose of ionizing radiation induce Alzheimer's disease-like alterations in mice? (2012) (0)
Wavelet DenoisingofDynamic PET Data: Application totheParametricImaging of PeripheralBenzodiazepineReceptor (2006) (0)
Serial and simultaneous PET measurement of fetal nigral transplantation in hemi-Parkinson model rats with [11C]PE2I and [11C]raclopride (2005) (0)
The high-affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET: 48.4 (2007) (0)
Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride (2010) (0)
Correlation between cerebral blood flow and amyloid deposition in Alzheimer's disease studied by [11C]PIB PET (2010) (0)
PET IMAGING OF SYNERGISTIC, BUT MODALLY DISTINCT OBESITY- AND AB-TRIGGERED ABNORMALITIES IN CEREBRAL GLUCOSE METABOLISM AND GLIOSIS IN MICE (2014) (0)
[Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors]. (2004) (0)
Quantification of dopamine transporter in human brain using positron emission tomography with 18F-FE-PE2I (2012) (0)
[Advances of neuroimaging research and the development of pathophysiology hypothesis for obsessive-compulsive disorder]. (2011) (0)
Noninvasive k3 estimation method for slow dissociation PET ligands: application to [11C]Pittsburgh compound B (2013) (0)
Lateral Amygdala Neurons Dopamine Induces a Slow Afterdepolarization in (2015) (0)
Aggregating interests in aggregates: mechanistic, diagnostic and therapeutic implications of brain amyloidosis in neurodegenerative disorders among the elderly (2005) (0)
Brain metabolic correlates of tau accumulation in progressive supranuclear palsy (2015) (0)
[Evaluation of drug therapy based on the results of imaging]. (2004) (0)
The analyze of four pedigrees with MAPT N279K mutation accompanying DAT scan and Tau imaging (2015) (0)
Differences of distribution between RO 15-1788 and RO 15-4513 in vivo. (1991) (0)
Dopamine Receptors in Schizophrenia (2002) (0)
90-25 Role of pulmonary binding site on pharmacokinetics of antidepressants measured by PET (1997) (0)
[Neuroimaging of neuropsychiatric disorders]. (2012) (0)
[Neural mechanisms of substance dependence]. (2010) (0)
Human Brain Imaging of Dopamine D1 Receptors (2014) (0)
Occupancy of dopamine transporter and the effect of dopamine reuptake inhibition by mazindol in living human brain (2013) (0)
International Scientific Advisory Committee (2012) (0)
IC-P-082 TAU AND ALPHA-SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIATHERAPEUTIC’S PM-PBB3 BINDING-SITE FOCUSED COMPOUND COLLECTION (2018) (0)
Reproducibility of binding potential in a single PET scan with multiple injections of [11C]raclopride to evaluate dopamine release (2013) (0)
Mitochondrial translocator protein (TSPO) ligand attenuates neuroinflammation and reduces complement component C1Q in a mouse model of tauopathy (2020) (0)
Aberrant prefrontal activation during false recognition in chronic alcoholics: A functional MRI study (2001) (0)
P2-079: Cortical amyloid deposition and parahippocampal atrophy in Alzheimer's disease and mild cognitive impairment (2008) (0)
216 – Functional abnormality of the extrastriate body area during observation of sports-related actions in chronic schizophrenia (2008) (0)
BrainPET Poster Session: Molecular Brain Imaging—Clinical Applications (2009) (0)
Comparative imaging between in vitro binding and in vivo PET (2010) (0)
Quantification of dopamine synthesis in human brain using positron emission tomography with l-[beta-11C]DOPA (2006) (0)
Preliminary analysis on DNA methylation status of marmoset model of psychiatric disorders with Infinium MethylationEPIC Kit (2017) (0)
Molecular imaging of mental disorders (2007) (0)
1 In Vivo SPECT Imaging of Amyloid-Deposition with Radioiodinated Imidazo [ 1 , 2-a ] pyridine Derivative DRM 106 in Mouse Model of Alzheimer ’ s Disease (2014) (0)
Differential Contribution of Dopaminergic Transmission at D1- and D2-like Receptors to Cost/Benefit Evaluation for Motivation in Monkeys (2020) (0)
Neural correlates of manipulation process and semantic access in working memory (2000) (0)
Lassen Award: Lassen Award Symposium (2009) (0)
Dopamine D1receptorsinParkinson's disease andstriatonigral degeneration: apositron emission tomography study (2017) (0)
Measurement Error Analysis for the Determination of Dopamine D2 Receptor Occupancy Using the Agonist Radioligand [11C]MNPA (2010) (0)
P1-266: Changes in beta-amyloid deposition by pet study (2008) (0)
Reply to Yang et al.: Gender is not a confounding factor of our result (2012) (0)
Diabetes-related dementia is associated with tau pathology rather than amyloid pathology (2017) (0)
New method of quantification of tau pathology with 11C-PBB3 PET using reference tissue extracted from cerebral cortical gray matter (2016) (0)
Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity by PET (2011) (0)
Healthy volunteer study using the helmet-neck PET prototype (2017) (0)
Histamine H3 Receptor is correlated with neural activity of executive function (2015) (0)
Kinetic analysis in healthy humans of [11C]PBR28, a new positron emission tomography radioligand to image the peripheral benzodiazepine receptor (2008) (0)
Correction for Radiolabeled O-Methyl Metabolite in Human Brain (2012) (0)
THE ROLE OF STEROID BIOSYNTHESIS IN THE PROTECTIVE ACTIONS OF LIGANDS FOR THE TRANSLOCATOR PROTEIN (TSPO) (2014) (0)
Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457 (2012) (0)
Synthesis and preliminary studies of a new nonpeptide antagonist for in vivo imaging of cholecystokinin‐a receptor (2001) (0)
Relation between pre- and postsynaptic dopaminergic functions measured by PET: Implication of dopaminergic tone (2010) (0)
Wavelet Denoising of Dynamic PET Data: Application to the Parametric Imaging of Peripheral Benzodiazepine Receptor (2006) (0)
Erratum to “Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [11C]PiB PET” [NeuroImage 143 (2016) 316–324] (2017) (0)
Evaluation of reference tissue models for the quantitative analysis of [11C]PE2I binding in human brain (2006) (0)
Representative immunofluorescence histological findings of tauopathy model mice and wild type mice. (2011) (0)
The high‐affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET. (2007) (0)
Parametric visualisation and quantification of tau pathology in human brain using PET with [C-11]PBB3 (2015) (0)
TAU ACCUMULATION PREDICTS PROGRESSION OF DEMENTIA IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE IN THE ALZHEIMER’S DISEASE SPECTRUM: A [11C]PBB3 POSITRON EMISSION TOMOGRAPHY STUDY (2018) (0)
Quantification and reference optimization of tau PET imaging with [11C] PBB3 in PSP patients (2016) (0)
[Usefulness of PET in clinical trials of psychotropic drugs]. (2005) (0)
Relationship between neuromelanin-weighted MRI contrast and PET radiotracer binding to dopamine transporter in substantia nigra (2013) (0)
Changes in dopaminergic function associated with low motivation in a primate model of hypothyroidism: a PET study (2011) (0)
Lewy body disease with dementia can be well-differentiated from Alzheimer's disease by measurement of cerebral cortical acetylcholinesterase activity by PET (2010) (0)
In vivo imaging of designer receptor that enables to modify reward-related behavior in monkeys (2014) (0)
Correlation between dopamine synthesis and cell-level structure in human striate body using diffusion tensor imaging and positron emission tomography with L-[ β-11 C ] DOPA (2009) (0)
Effective Biomarkers for Proof-of-Concept (2008) (0)
BrainPET Poster Session: in vivo Pharmacology and Clinical Applications (2009) (0)
In vivo detection of amyloid deposition using [11C]AZD2184 PET (2012) (0)
Vocalization pattern analysis in the common marmosets (Callithrix jacchus);Novel method to classify emotional states of animals (2010) (0)
In-vivo PET detection of neurodegenerative pathologies in a transgenic mouse model of tauopathies (2009) (0)
Visualization of tau lesions in brains of tauopathy patients and model mice using tau ligand PBB3 (2014) (0)
RADIOLIGAND BINDING ASSAYS FOR COMPARISON OF TAU PET PROBES, PBB3 AND T807, IN DETECTION OF TAU PATHOLOGIES IN ALZHEIMER'S DISEASE AND PSP BRAINS, AND NEUROTOXIC TAU SPECIES IN A TRANSGENIC MOUSE MODEL (2016) (0)
Chronic treatment with serotonergic antidepressants alters both serotonin and dopamine receptor expressions in mouse hippocampus (2010) (0)
PET examination of the monkey heart with high specific radioactivity [11C]norepinephrine and [11C]metaraminol. (1995) (0)
Effect of lithium and anesthetics on in vivo binding of dopamine receptors. (1991) (0)
Selective autophagy in neurons and its involvement in tau pathogenesis (2012) (0)
[Significance of imaging biomarkers in exploratory clinical trials]. (2009) (0)
Serotonergic Neurotransmission in Limbic Regions May Reflect Therapeutic Response of Depressive Patients: A PET Study with 11C-WAY-100635 and 18F-MPPF (2022) (0)
Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants (2020) (0)
PET molecular imaging of Psychiatric Disorders (2008) (0)
Alteration of dopaminergic function in a primate model of hypothyroidism revealed by PET (2011) (0)
Quantitative assessment of prenatal X-ray exposure using longitudinal gadolinium-, manganese-enhanced and perfusion MRI in neonatal rats (2009) (0)
Brain PET Oral 4: in vivo Pharmacology I—Dopamine and Norepinephrine (2009) (0)
13. The preliminary phantom study for in vivo pharmacokinetics of antipsycotic drug fluvoxamine using commercial MRI system 19F-MRS (2001) (0)
Evaluation of radiotherapy using Manganese-enhanced MRI ( MEMRI ) (2009) (0)
PIVOTAL ROLES OF P62 AND SELECTIVE AUTOPHAGY IN NEURODEGENERATION REVEALED WITH TAUOPATHY MOUSE MODELS (2014) (0)
Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET (2016) (0)
IN VIVO TRACKING OF TAU PATHOLOGIES WITH 18F-PM-PBB3 (18F-APN-1607) PET IN AD AND DIVERSE NON-AD TAUOPATHIES (2019) (0)
BrainPET Poster Session: Radiotracers and Quantification (2009) (0)
VISUALIZATION OF MICROGLIAL RESPONSE TO TAU-INDUCED NEURODEGENERATION IN A MODEL OF TAUOPATHY (2017) (0)
Comparison of image reconstruction methods in estimating of human neuroreceptor binding with PET (2008) (0)
[Molecular imaging in the drug development of psychotropics using positron emission tomography]. (2007) (0)
2.022 EFFECT OF PRAMIPEXOLE ON REGIONAL CEREBRAL BLOOD FLOW IN PARKINSON'S DISEASE (2012) (0)
Tau deposition estimated by [11C]PBB3 PET in Alzheimer’s disease, MCI with and without amyloid deposition, and cognitive healthy subjects (2014) (0)
Effects of the partial agonist antipsychotic drug aripiprazole on dopamine synthesis in humans measured by PET with [C-11]DOPA (2012) (0)
Neuroscience Committee (2008) (0)
Conformational heterogeneity of tau lesions captured by PET and its clinical significance (2016) (0)
Effects of antipsychotic drug on dopamine synthesis in humans measured by PET with [C-11]DOPA (2009) (0)
TAU AND ALPHA-SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC’S PM-PBB3 BINDING-SITE FOCUSED COMPOUND COLLECTION (2018) (0)
Significance of 18-kDa translocator protein in monitoring and regulating microglial response to Aβ amyloidosis: An in vivo PET study of microglia-implanted mouse models (2010) (0)
Influence of maternal immune activation in embryonic stage on hippocampal function in juvenile stage (2009) (0)
Reproducibility of [11C]MNPA binding in healthy human subjects (2010) (0)
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys (2020) (0)
Resting-state functional connectivity relates to interindividual variations in positive memory. (2021) (0)
P-059 Voxel-based analysis of [11C]PIB uptake in Alzheimer’s disease and mild cognitive impairment (2007) (0)
PET IMAGING OF SYNERGISTIC, BUT MODALLY DISTINCT, OBESITY- AND Aβ-TRIGGERED ABNORMALITIES IN CEREBRAL GLUCOSE METABOLISM AND GLIOSIS IN MICE (2014) (0)
Roles of hippocampal and prefrontal dopamine D1 and D2 receptors in human neurocognitive functions (2008) (0)
Lewy Body Disease With Dementia can be Well-Differentiated from Alzheimer's Disease By Measurement of Cerebral Cortical Acetylcholinesterase Activity by PET (2010) (0)
Performance prediction of candidate PET ligands for central histamine H3 receptor by liquid chromatography-tandem mass spectrometry (2014) (0)
Quantitative multi-parametric assessment of a radiation-induced encepholodysplasia CNS model using magnetic resonance imaging (2010) (0)
Serotonergic neural network related to behavioral inhibition system (2021) (0)
Quantitative analysis of NK1 receptor binding in human brain using PET with [18F]FE-SPA-RQ (2008) (0)
A biological homology between a rodent model of maternal immune activation and schizophrenia patients: A comparative study using positron emission tomography and immune histochemistry (2011) (0)
P1-277 SPECT IMAGING FOR AMYLOID PLAQUESWITH A NOVEL RADIOIODINATED LIGAND IN AN ALZHEIMER’S DISEASE MODEL (2014) (0)
Reduction of dopmamine D2 receptor binding in medial prefrontal cortex in schizophrenia animal model with maternal immune activation (2010) (0)
[Effect of menopause on morphological changes of the brain in schizophrenia]. (2013) (0)
TAU AND ALPHA-SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC’S PM-PBB3 BINDING-SITE FOCUSED COMPOUND COLLECTION (2018) (0)
A tau PET study of primary age‐related tauopathy in healthy volunteers (2020) (0)
CORRELATION BETWEEN SEVERITY OF PARKINSONISM AND DOPAMINE NEURONAL DAMAGE IN MPTP-TREATED MARMOSETS (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tetsuya Suhara?

Tetsuya Suhara is affiliated with the following schools:

Tetsuya Suhara's Academic­Influence.com Rankings

Tetsuya Suhara's Degrees

Why Is Tetsuya Suhara Influential?

Tetsuya Suhara's Published Works

Published Works

What Schools Are Affiliated With Tetsuya Suhara?

Tetsuya Suhara's AcademicInfluence.com Rankings